de Lucena Valim Juliana Miranda, Gonçalves Chaer Fernanda Gomes, Guimarães da Silveira Fernanda D'Oliveira, da Silva E Lima Verônica Palmiro, Batista de Souza Branca Dias
Médica assistente da Reumatologia da ISCMSP, Medicine Department/Rheumatology Division, Santa Casa de Misericórdia de São Paulo, São Paulo-SP/CEP 01221-900, Brazil.
Médica residente da Reumatologia da ISCMSP, Medicine Department/Rheumatology Division, Santa Casa de Misericórdia de São Paulo, São Paulo-SP/CEP 01221-900, Brazil.
Future Sci OA. 2018 Dec 4;5(1):FSO355. doi: 10.4155/fsoa-2018-0025. eCollection 2019 Jan.
To assess drug switching, rates of remission and disease activity in Brazilian patients with rheumatoid arthritis (RA) treated with biologic agents.
MATERIALS & METHODS: Using a retrospective method, a total of 94 adult patients were included.
Anti-TNF was the first choice therapy in 85 (90.4%) patients. After an average of 8 years of follow-up, 55 (59%) patients were taking anti-TNF, 18 (19%) abatacept, eight (9%) tocilizumab and 13 (14%) rituximab. In this period, 99 switches of biological therapy were registered in 55 patients.
After 8 years of follow-up, 54% of the RA patients on biological therapy were still experiencing high or moderate activity despite established treatment, including switching between different biologic agents.
评估接受生物制剂治疗的巴西类风湿关节炎（RA）患者的药物转换、缓解率和疾病活动度。
采用回顾性方法，共纳入94例成年患者。
85例（90.4%）患者将抗TNF作为首选治疗。平均随访8年后，55例（59%）患者服用抗TNF，18例（19%）服用阿巴西普，8例（9%）服用托珠单抗，13例（14%）服用利妥昔单抗。在此期间，55例患者记录了99次生物治疗转换。
随访8年后，54%接受生物治疗的RA患者尽管已接受既定治疗，但仍处于高活动度或中度活动度，包括在不同生物制剂之间转换。
